Breaking News Instant updates and real-time market news.

LAD

Lithia Motors

$116.17

0.01 (0.01%)

, UPLD

Upland Software

$47.40

-0.66 (-1.37%)

10:04
05/31/19
05/31
10:04
05/31/19
10:04

Fly Intel: Top five analyst initiations

Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Lithia Motors (LAD) initiated with a Buy at Longbow. 2. Upland Software (UPLD) initiated with a Buy at Jefferies. 3. Alkermes (ALKS) initiated with a Neutral at H.C. Wainwright. 4. Twist Bioscience (TWST) initiated with an Outperform at Evercore ISI. 5. CyberArk (CYBR) initiated with a Buy at Berenberg. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.

LAD

Lithia Motors

$116.17

0.01 (0.01%)

UPLD

Upland Software

$47.40

-0.66 (-1.37%)

ALKS

Alkermes

$22.02

-0.02 (-0.09%)

TWST

Twist Bioscience

$26.10

-0.48 (-1.81%)

CYBR

CyberArk

$131.11

-1.04 (-0.79%)

  • 31

    May

  • 04

    Jun

  • 05

    Jun

  • 12

    Jun

  • 13

    Nov

LAD Lithia Motors
$116.17

0.01 (0.01%)

04/26/19
BOFA
04/26/19
DOWNGRADE
BOFA
Neutral
Lithia Motors downgraded to Neutral on valuation at BofA/Merrill
BofA/Merrill analyst John Murphy downgraded Lithia Motors to Neutral from Buy citing valuation following the recent share strength since the Q1 report. Murphy raised Lithia's price target to $115 from $102 to reflect improved growth in the Parts & Service and Used vehicle segments.
05/06/19
MSCO
05/06/19
UPGRADE
Target $94
MSCO
Overweight
Morgan Stanley more positive on auto dealers, upgrades Group 1 to Overweight
As previously reported, Morgan Stanley analyst Armintas Sinkevicius upgraded Group 1 Automotive (GPI) to Overweight from Equal Weight as he turns positive on the traditional auto dealer group and named it his top pick among the traditional dealers. Sinkevicius sees the potential for an elongated auto cycle following changes to the Fed policy, he noted, adding that he is also drawn to the defensiveness of the dealer model and investor positioning. The analyst, who noted that his estimates are above consensus for all of the traditional dealers in Q2 and for 2019, raised his price target on Group 1 shares to $94 from $67, raised his target on Asbury Automotive (ABG) to $87 from $85, upped his target on AutoNation (AN) to $36 from $27, raised his target on Lithia Motors (LAD) to $128 from $117, increased his target on Sonic Automotive (SAH) to $18 from $10 and keeps a $56 price target on Penske Automotive (PAG).
05/31/19
LBOW
05/31/19
INITIATION
Target $132
LBOW
Buy
Lithia Motors initiated with a Buy at Longbow
Longbow analyst Anthony Deem initiated Lithia Motors with a Buy and $132 price target.
05/31/19
LBOW
05/31/19
INITIATION
Target $132
LBOW
Buy
Longbow starts Lithia Motors at Buy on 'defensive' earnings profile
Longbow analyst Anthony Deem initiated coverage of Lithia Motors with a Buy rating and $132 price target. Annual earnings growth of 5%-10% appears likely over the next several years, driven by same-store revenue and GPU growth, stabilizing interest rates, and share buybacks, Deem tells investors in a research note. Further, the analyst believes accretion from Lithia's capital deployment is likely to "remain robust" with acquisitions picking up potentially in the second half of 2019 or early 2020. He views the company's earnings profile as "defensive."
UPLD Upland Software
$47.40

-0.66 (-1.37%)

05/06/19
ADAM
05/06/19
NO CHANGE
Target $52
ADAM
Buy
Upland Software price target raised to $52 from $42 at Canaccord
Canaccord analyst Richard Davis raised his price target for Upland Software to $52 and maintained a Buy rating, saying Upland's management has executed well along its path. Beating and raising when a stock is reasonably valued in an overheating valuation world for software suggests that this stock is worthy of investment consideration, Davis tells investors in a research note.
05/31/19
CHLM
05/31/19
NO CHANGE
Target $56
CHLM
Buy
Upland Software price target raised to $56 from $52 at Craig-Hallum
Craig-Hallum analyst Jeff Van Rhee raised his price target for Upland Software to $56 from $52 following the Kapost deal. In a research note to investors, Van Rhee says he believes the increased liquidity will allow Upland to tap the term B debt market in the nearer team to lower their interest rate somewhat and gain more favorable covenants and terms. He also believes the runway for Upland to continue executing their best-in-class acquisition/onboarding engine is very long and he continues to think organic growth, while likely to be volatile in the near term, will see upward pressure in the intermediate term, increasing the likelihood of a re-rate. He maintains a Buy rating.
05/31/19
JEFF
05/31/19
INITIATION
Target $61
JEFF
Buy
Upland Software initiated with a Buy at Jefferies
Jefferies analyst John DiFucci started Upland Software with a Buy rating and $61 price target. The company is "unique" with a "highly effective" approach to investing in and operating software assets, DiFucci tells investors in a research note. The analyst views the current valuation as attractive and believes Upland's guidance is conservative.
05/28/19
ROTH
05/28/19
NO CHANGE
Target $58
ROTH
Buy
Upland Software price target raised to $58 after Kapost deal at Roth Capital
After Upland Software announced it has acquired content operations platform provider Kapost in a deal that the company sees being immediately accretive to adjusted EBITDA per share, Roth Capital analyst Richard Baldry raised his price target on Upland shares to $58 from $54. He believes the company's rapidly increasing adjusted EBITDA highlights the strength of its strategy and thinks its superior profitability and proven acquisition strategy should support the stock's valuation. Baldry keeps a Buy rating on Upland shares.
ALKS Alkermes
$22.02

-0.02 (-0.09%)

05/01/19
SBSH
05/01/19
DOWNGRADE
Target $33
SBSH
Neutral
Alkermes downgraded to Neutral from Buy at Citi
Citi analyst Liav Abraham downgraded Alkermes to Neutral from Buy and lowered her price target for the shares to $33.
05/01/19
05/01/19
DOWNGRADE

Fly Intel: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. McDonald's (MCD) downgraded to Neutral from Buy at Longbow with analyst Alton Stump saying while the company's "impressive" U.S. comp growth in Q1 increases his confidence in comps over the last three quarters of the year, he also believes the stock reflects his favorable view with shares trading near his prior price target of $200. 2. Sabre (SABR) downgraded to Market Perform from Outperform at William Blair with analyst Matthew Pfau saying that while the company outperformed in Q1, it lowered guidance across all headline metrics. 3. Alkermes (ALKS) downgraded to Neutral from Buy at Citi with analyst Liav Abraham saying while the positive Phase 3 data for ALKS 3831 in Q4 support a constructive view on the compound, there are not "sufficient meaningful catalysts to drive material upside" in the stock for the remainder of 2019. 4. Tile Shop (TTS) downgraded to Neutral from Buy at Citi with analyst Geoffrey Small saying the company's turnaround "showed encouraging progress" in the second half of 2018, but the Q1 results "represented a sizeable step back." 5. Cummins (CMI) downgraded to Hold from Buy at Loop Capital with analyst Jeffrey Kauffman saying he believes good news is mostly priced into the shares at current valuation levels. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
05/31/19
HCWC
05/31/19
INITIATION
Target $28
HCWC
Neutral
Alkermes initiated with a Neutral at H.C. Wainwright
H.C. Wainwright analyst Douglas Tsao started Alkermes with a Neutral rating and $28 price target. While Vivitrol and Aristada should see continued growth, they're showing signs of maturity, necessitating Alkermes to bring new products to market to sustain growth, Tsao tells investors in a research note. The analyst also lacks conviction on the commercial potential of ALKS-3831.
05/01/19
SBSH
05/01/19
DOWNGRADE
Target $33
SBSH
Neutral
Citi downgrades Alkermes to Neutral on lack of upside catalysts
Citi analyst Liav Abraham downgraded Alkermes to Neutral from Buy and cut her price target for the shares to $33 from $62. The analyst says that while the positive Phase 3 data for ALKS 3831 in Q4 support a constructive view on the compound, there are not "sufficient meaningful catalysts to drive material upside" in the stock for the remainder of 2019. FDA submission of ALKS 3831 in mid-2019 and potential approval of ALKS 8700 in Q4 are well expected at this point, Abraham tells investors in a research note. Further, she believes growth of Alkermes' key branded products, Vivitrol and Aristada, is expected to remain "moderate at best" over the near to medium term. As such, the analyst struggles to find reasons to be buyers of the stock at the moment.
TWST Twist Bioscience
$26.10

-0.48 (-1.81%)

11/26/18
11/26/18
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Nvidia (NVDA) initiated with an Outperform at Credit Suisse. 2. Orchard Therapeutics (ORTX) initiated with an Outperform at Wedbush and Cowen, an Overweight at JPMorgan, and a Neutral at Goldman Sachs. 3. Twist Bioscience (TWST) initiated with an Outperform at Cowen and Baird as well as a Neutral at JPMorgan. 4. Axonics (AXNX) initiated with a Buy at BofA/Merrill and SunTrust, an Outperform at Wells Fargo, and an Overweight at Morgan Stanley. 5. Gamida Cell (GMDA) initiated with a Buy at Needham. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
05/31/19
EVER
05/31/19
INITIATION
Target $30.5
EVER
Outperform
Twist Bioscience initiated with an Outperform at Evercore ISI
Evercore ISI analyst Ross Muken initiated Twist Bioscience with an Outperform rating and $30.50 price target, telling investors that disruptive potential of synthetic biology is "massive" across industries. Twist's core business of DNA synthesis and its NGS Tools business give it "two shots on goal" to maintain greater than 25% growth over the next 3-5 years. Investors in the stock also get "two call options," namely the company's potential to provide synthetic RNA and DNA to RNAi therapeutic companies to help develop APIs and its potential to use DNA as a storage medium.
11/26/18
BARD
11/26/18
INITIATION
Target $30
BARD
Outperform
Twist Bioscience initiated with an Outperform at Baird
Baird analyst Catherine Ramsey Schulte initiated Twist Bioscience with an Outperform rating citing its silicon-based chip technology that can create high quality synthetic DNA on a large scale with cost effectiveness. She sees a large market opportunity with broad applications. Schulte has a $30 price target on Twist Bioscience shares.
11/26/18
COWN
11/26/18
INITIATION
COWN
Outperform
Twist Bioscience initiated with an Outperform at Cowen
Cowen analyst Doug Schenkel initiated Twist Bioscience with an Outperform rating, citing its scalable commercial platform to industrialize the synthetic engineering of DNA. He said its positioning and market opportunity warrant a premium valuation. Schenkel has not established a price target yet for Twist Bioscience shares.
CYBR CyberArk
$131.11

-1.04 (-0.79%)

05/14/19
JMPS
05/14/19
NO CHANGE
Target $135
JMPS
Outperform
CyberArk price target raised to $135 from $130 at JMP Securities
JMP Securities analyst Erik Suppiger raised his price for CyberArk to $135 from $130 after the company reported "strong" Q1 results, and provided Q2 and 2019 guidance higher than consensus. The analyst reiterates an Outperform rating on the shares as he continues to believe that CyberArk is "undervalued."
05/15/19
OPCO
05/15/19
NO CHANGE
Target $130
OPCO
Outperform
CyberArk price target raised to $130 from $111 at Oppenheimer
Oppenheimer analyst Shaul Eyal raised his price target for CyberArk to $130 from $111, citing "strong" Q1 start, consistent "solid" execution and elevated 2019 guidance. The analyst reiterates an Outperform rating on the shares.
05/31/19
BREN
05/31/19
INITIATION
Target $155
BREN
Buy
CyberArk initiated with a Buy at Berenberg
Berenberg analyst Joshua Tilton started CyberArk with a Buy rating and $155 price target, stating that the adoption of cloud and modern application and development architectures are "exponentially increasing" the number of privileged credentials that must be secured and managed by enterprises. He expects this trend, plus the company's plans to enter the mid-market, to support continued top-line growth.
04/25/19
04/25/19
DOWNGRADE

Fly Intel: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Tesla (TSLA) downgraded to Neutral from Outperform at Wedbush with analyst Daniel Ives saying the demand story is quickly changing and the company has "unfortunately not adjusted to an evolving EV landscape." 2. PTC (PTC) downgraded to Underweight from Neutral at JPMorgan, to Underperform from Neutral at BofA/Merrill, and to Neutral on IoT/AR uncertainties at Wedbush. 3. Xilinx (XLNX) downgraded to Hold from Buy at Needham and to Neutral from Buy at Goldman Sachs. 4. Spirit Airlines (SAVE) downgraded to Neutral from Buy at BofA/Merrill with analyst Andrew Didora saying industry pricing has not improved and sees some cost pressures that limit upside potential. 5. CyberArk (CYBR) downgraded to Neutral from Buy at UBS with analyst Fatima Boolani saying she remains bullish on the company's fundamentals as well as its execution consistency and "expanding mindshare in a market gone mainstream," which have accelerated the company's revenue growth to over 30% and supported the 70% year-to-date run-up in the stock price. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.

TODAY'S FREE FLY STORIES

UNH

UnitedHealth

$247.78

-2.47 (-0.99%)

19:29
06/20/19
06/20
19:29
06/20/19
19:29
Periodicals
UnitedHealth to acquire Equian from New Mountain Capital, WSJ says »

UnitedHealth has reached…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Jun

  • 18

    Jul

KFY

Korn/Ferry

$48.61

1.04 (2.19%)

, EXEL

Exelixis

$21.14

0.15 (0.71%)

19:05
06/20/19
06/20
19:05
06/20/19
19:05
Hot Stocks
Fly Intel: After Hours Movers »

DOWN AFTER EARNINGS:…

KFY

Korn/Ferry

$48.61

1.04 (2.19%)

EXEL

Exelixis

$21.14

0.15 (0.71%)

SEE

Sealed Air

$43.68

-0.13 (-0.30%)

PYPL

PayPal

$118.82

1.66 (1.42%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Jun

EXEL

Exelixis

$21.14

0.15 (0.71%)

, RHHBY

Roche

$0.00

(0.00%)

19:01
06/20/19
06/20
19:01
06/20/19
19:01
Hot Stocks
Exelixis informed by Genentech that IMspire170 did not meet primary endpoint »

In a regulatory 8-k…

EXEL

Exelixis

$21.14

0.15 (0.71%)

RHHBY

Roche

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Jun

  • 27

    Jun

  • 06

    Aug

  • 18

    Aug

  • 19

    Aug

  • 26

    Aug

  • 02

    Sep

  • 04

    Nov

INVH

Invitation Homes

$27.68

-0.07 (-0.25%)

18:55
06/20/19
06/20
18:55
06/20/19
18:55
Syndicate
Invitation Homes 37.5M share Spot Secondary priced at ~$26.67 »

The deal priced for $1B…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Jun

MDB

MongoDB

$173.76

-0.33 (-0.19%)

18:44
06/20/19
06/20
18:44
06/20/19
18:44
Hot Stocks
MongoDB CEO: Every company is becoming a software company »

In an interview on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Jul

VRML

Vermillion

$0.89

-0.1575 (-15.00%)

18:37
06/20/19
06/20
18:37
06/20/19
18:37
Hot Stocks
Vermillion adds two contracted agreements for OVA1 cancer risk test »

Vermillion has further…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CAT

Caterpillar

$133.66

2.97 (2.27%)

18:34
06/20/19
06/20
18:34
06/20/19
18:34
Hot Stocks
Caterpillar CEO: We take a long-term view »

In an interview on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

UNH

UnitedHealth

$247.78

-2.47 (-0.99%)

18:22
06/20/19
06/20
18:22
06/20/19
18:22
Periodicals
Breaking Periodicals news story on UnitedHealth »

UnitedHealth said to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Jun

  • 18

    Jul

BKS

Barnes & Noble

$6.71

0.055 (0.83%)

18:20
06/20/19
06/20
18:20
06/20/19
18:20
Downgrade
Barnes & Noble rating change at Gabelli »

Barnes & Noble…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CSGP

CoStar Group

$555.39

-0.78 (-0.14%)

18:11
06/20/19
06/20
18:11
06/20/19
18:11
Hot Stocks
CoStar Group acquires Off Campus Partners »

CoStar Group has acquired…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Nov

BDX

Becton Dickinson

$245.32

7.2 (3.02%)

17:55
06/20/19
06/20
17:55
06/20/19
17:55
Hot Stocks
Becton Dickinson backs safety of its Lutonix drug-coated balloons in SFA »

BD issued the following…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Jun

CPF

Central Pacific

$28.49

-0.13 (-0.45%)

17:41
06/20/19
06/20
17:41
06/20/19
17:41
Hot Stocks
Central Pacific authorizes buyback of up to $30M in common stock »

Central Pacific announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Nov

  • 07

    Nov

  • 08

    Nov

AEL

American Equity

$27.51

0.3 (1.10%)

17:33
06/20/19
06/20
17:33
06/20/19
17:33
Hot Stocks
American Equity director Debra Richardson sells almost $2.2M in company shares »

American Equity director…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SEE

Sealed Air

$43.68

-0.13 (-0.30%)

17:28
06/20/19
06/20
17:28
06/20/19
17:28
Earnings
Sealed Air backs FY19 adjusted EPS view $2.65-$2.75, consensus $2.73 »

Sealed Air continues to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SEE

Sealed Air

$43.68

-0.13 (-0.30%)

17:27
06/20/19
06/20
17:27
06/20/19
17:27
Hot Stocks
Sealed Air names James Sullivan as new CFO, effective June 24 »

Sealed Air announced it…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AJRD

Aerojet Rocketdyne

$43.01

1.49 (3.59%)

17:27
06/20/19
06/20
17:27
06/20/19
17:27
Hot Stocks
Aerojet Rocketdyne subsidiary awarded $140.18M missile defense modification »

Coleman Aerospace, a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SEE

Sealed Air

$43.68

-0.13 (-0.30%)

17:25
06/20/19
06/20
17:25
06/20/19
17:25
Hot Stocks
Sealed Air terminates CFO William Stiehl for cause, effective immediately »

Sealed Air announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BBU

Brookfield Business Partners

$41.25

1.28 (3.20%)

, BAM

Brookfield

$48.38

0.29 (0.60%)

17:15
06/20/19
06/20
17:15
06/20/19
17:15
Syndicate
Brookfield Business Partners announces $795M equity offering »

Brookfield Business…

BBU

Brookfield Business Partners

$41.25

1.28 (3.20%)

BAM

Brookfield

$48.38

0.29 (0.60%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Aug

AXLA

Axcella

$10.39

0.27 (2.67%)

17:13
06/20/19
06/20
17:13
06/20/19
17:13
Earnings
Axcella reports Q1 EPS ($2.43), consensus (49c) »

Q1 operating expenses…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LKSD

LSC Communications

$5.83

0.07 (1.22%)

17:11
06/20/19
06/20
17:11
06/20/19
17:11
Hot Stocks
LSC comments on DOJ action regarding proposed transaction with Quad »

LSC Communications…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

QUAD

Quad/Graphics

$9.75

0.09 (0.93%)

, LKSD

LSC Communications

$5.83

0.07 (1.22%)

17:10
06/20/19
06/20
17:10
06/20/19
17:10
Hot Stocks
Quad/Graphics intends to defend proposed LSC Communications acquisition »

Quad/Graphics (QUAD)…

QUAD

Quad/Graphics

$9.75

0.09 (0.93%)

LKSD

LSC Communications

$5.83

0.07 (1.22%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SFM

Sprouts Farmers Market

$19.52

0.14 (0.72%)

17:04
06/20/19
06/20
17:04
06/20/19
17:04
Hot Stocks
Sprouts Farmers Market interim co-CEO/CFO Brad Lukow resigns »

Sprouts Farmers Market…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Nov

NAKD

Naked Brand Group

$0.27

0.0025 (0.93%)

17:03
06/20/19
06/20
17:03
06/20/19
17:03
Syndicate
Breaking Syndicate news story on Naked Brand Group »

Naked Brand Group files…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HPQ

HP Inc.

$20.85

0.22 (1.07%)

16:57
06/20/19
06/20
16:57
06/20/19
16:57
Hot Stocks
HP Inc. General Counsel sells 20K shares of common stock »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jun

  • 01

    Jul

  • 02

    Jul

  • 03

    Jul

  • 04

    Jul

CPT

Camden Property

$107.61

0.57 (0.53%)

16:54
06/20/19
06/20
16:54
06/20/19
16:54
Hot Stocks
Camden Property COO sells 16.2K shares of common stock »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.